Safety of an Ultra-Rush Immunotherapy Build-Up Schedule with Therapeutic Vaccines Containing Depigmented and Polymerized Allergen Extracts

2006 ◽  
Vol 139 (2) ◽  
pp. 153-158 ◽  
Author(s):  
M. Casanovas ◽  
R. Martín ◽  
C. Jiménez ◽  
R. Caballero ◽  
E. Fernández-Caldas
Keyword(s):  
Therapeutic Vaccines ◽  
Rush Immunotherapy ◽  
Allergen Extracts

Safety of immunotherapy with therapeutic vaccines containing depigmented and polymerized allergen extracts

2007 ◽  
Vol 37 (3) ◽  
pp. 434-440 ◽  
Author(s):  
M. Casanovas ◽  
R. Martín ◽  
C. Jiménez ◽  
R. Caballero ◽  
E. Fernández-Caldas
Keyword(s):  
Therapeutic Vaccines ◽  
Allergen Extracts

scholarly journals Safety and Utility of Rush Immunotherapy with Aqueous Allergen Extracts for the Treatment of Respiratory Allergies

2021 ◽  
Vol 36 (3) ◽  
Author(s):  
Ji-Ho Lee ◽  
Jae-Hwa Choi ◽  
Keun-Bae Jeong ◽  
Seok Jeong Lee ◽  
Myoung Kyu Lee ◽  
...  
Keyword(s):  
Respiratory Allergies ◽  
Rush Immunotherapy ◽  
Allergen Extracts

Safety of a rush immunotherapy build-up schedule with depigmented polymerized allergen extracts

2010 ◽  
Vol 31 (3) ◽  
pp. 31-38 ◽  
Author(s):  
Randolf Brehler ◽  
Ludger Klimek ◽  
Oliver Pfaar ◽  
Bettina Hauswald ◽  
Margitta Worm ◽  
...  
Keyword(s):  
Rush Immunotherapy ◽  
Allergen Extracts

scholarly journals Rush immunotherapy in two cats with atopic skin syndrome

2021 ◽  
Vol 7 (1) ◽  
pp. 205511692110233
Author(s):  
Selene Jones ◽  
Paul Bloom
Keyword(s):  
Treatment Option ◽  
Adverse Reactions ◽  
Clinical Signs ◽  
Case Series ◽  
Protein Nitrogen ◽  
Intradermal Testing ◽  
Alternative Treatment Option ◽  
Atopic Skin ◽  
Rush Immunotherapy ◽  
Allergen Extracts

Case series summary Two cats with feline atopic skin syndrome (FASS) were included in this case series. They were diagnosed with FASS by a combination of history, physical examination and exclusion of other pruritic diseases. They underwent rush immunotherapy (RIT) after determination of offending environmental allergens by either serum IgE or intradermal testing. Cats were premedicated with an antihistamine and hospitalized for the day to undergo the procedure and to ensure adequate observation. Allergen extracts were administered subcutaneously at increasing concentrations every 30 mins until the maintenance dose of 20,000 protein nitrogen units/ml was reached. Both cats successfully completed RIT without any adverse reactions and their clinical signs improved afterwards. RIT appears to be an alternative treatment option for cats with FASS. Larger studies are needed to more accurately assess the safety and long-term efficacy of RIT in the feline patient, as well as the incidence of adverse reactions and optimal premedication protocol. Further evaluation of the route of injections for RIT is also warranted. Relevance and novel information RIT has been reported to be a safe treatment option in canine atopic dermatitis. Its use in FASS is limited to a pilot study of four cats. The purpose of this series was to describe two additional cats that underwent RIT using a different premedication protocol.

Therapeutic Vaccines against Melanoma

2017 ◽  
Vol 33 (6) ◽  
pp. 4-11
Author(s):  
E.V. Starostina ◽  
◽  
E.A. Borobova ◽  
L.I. Karpenko ◽  
A.A. Ilyichev ◽  
...  
Keyword(s):  
Therapeutic Vaccines

scholarly journals Magnetic Nanostructures as Emerging Therapeutic Tools to Boost Anti-Tumour Immunity

Cancers ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 2735
Author(s):  
Stefano Persano ◽  
Pradip Das ◽  
Teresa Pellegrino
Keyword(s):  
Cancer Immunotherapy ◽  
Low Cost ◽  
Drug Stability ◽  
Adoptive Cell Therapy ◽  
Magnetic Nanostructures ◽  
Immune Checkpoint Blockade ◽  
Therapeutic Vaccines ◽  
Durable Response ◽  
Tumour Immunity ◽  
Therapeutic Modalities

Cancer immunotherapy has shown remarkable results in various cancer types through a range of immunotherapeutic approaches, including chimeric antigen receptor-T cell (CAR-T) therapy, immune checkpoint blockade (ICB), and therapeutic vaccines. Despite the enormous potential of cancer immunotherapy, its application in various clinical settings has been limited by immune evasion and immune suppressive mechanisms occurring locally or systemically, low durable response rates, and severe side effects. In the last decades, the rapid advancement of nanotechnology has been aiming at the development of novel synthetic nanocarriers enabling precise and enhanced delivery of immunotherapeutics, while improving drug stability and effectiveness. Magnetic nanostructured formulations are particularly intriguing because of their easy surface functionalization, low cost, and robust manufacturing procedures, together with their suitability for the implementation of magnetically-guided and heat-based therapeutic strategies. Here, we summarize and discuss the unique features of magnetic-based nanostructures, which can be opportunely designed to potentiate classic immunotherapies, such as therapeutic vaccines, ICB, adoptive cell therapy (ACT), and in situ vaccination. Finally, we focus on how multifunctional magnetic delivery systems can facilitate the anti-tumour therapies relying on multiple immunotherapies and/or other therapeutic modalities. Combinatorial magnetic-based therapies are indeed offering the possibility to overcome current challenges in cancer immunotherapy.

scholarly journals Prospects of immune checkpoint blockade and vaccine-based immunotherapy for glioblastoma

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Stefanie Tietze ◽  
Susanne Michen ◽  
Gabriele Schackert ◽  
Achim Temme
Keyword(s):  
Immune Checkpoint ◽  
Checkpoint Inhibitors ◽  
Primary Brain Tumor ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade ◽  
Oncolytic Viruses ◽  
Therapeutic Vaccines ◽  
Dismal Prognosis ◽  
Tumor Parenchyma ◽  
Immunosuppressive Microenvironment

Abstract Glioblastoma multiforme (GBM) is the most prevalent primary brain tumor endowed with a dismal prognosis. Nowadays, immunotherapy in a particular immune checkpoint blockade and therapeutic vaccines are being extensively pursued. Yet, several characteristics of GBM may impact such immunotherapeutic approaches. This includes tumor heterogeneity, the relatively low mutational load of primary GBM, insufficient delivery of antibodies to tumor parenchyma and the unique immunosuppressive microenvironment of GBM. Moreover, standard treatment of GBM, comprising temozolomide chemotherapy, radiotherapy and in most instances the application of glucocorticoids for management of brain edema, results in a further increased immunosuppression. This review will provide a brief introduction to the principles of vaccine-based immunotherapy and give an overview of the current clinical studies, which employed immune checkpoint inhibitors, oncolytic viruses-based vaccination, cell-based and peptide-based vaccines. Recent experiences as well as the latest developments are reviewed. Overcoming obstacles, which limit the induction and long-term immune response against GBM when using vaccination approaches, are necessary for the implementation of effective immunotherapy of GBM.

Sign in / Sign up

Export Citation Format

Share Document